Population approach for exposure-response modeling of golimumab in patients with rheumatoid arthritis

Journal of Clinical Pharmacology

Volumn 51, Issue 5, 2011, Pages 639-648

  Hu, Chuanpu ^a   Xu, Zhenhua ^a   Zhang, Yi ^a   Rahman, Mahboob U ^a,b   Davis, Hugh M ^a   Zhou, Honghui ^a  

^a CENTOCOR INC   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

golimumab; Monoclonal antibody; NONMEM; population pharmacokinetic pharmacodynamic modeling; rheumatoid arthritis

Indexed keywords

GOLIMUMAB; METHOTREXATE; PLACEBO;

ACCURACY; ADULT; AGED; AMERICAN COLLEGE OF RHEUMATOLOGY INDEX OF IMPROVEMENT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOLOGICAL PARAMETERS; PHASE 3 CLINICAL TRIAL; RATING SCALE; RHEUMATOID ARTHRITIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS; LIKELIHOOD FUNCTIONS; MALE; METHOTREXATE; MIDDLE AGED; MODELS, BIOLOGICAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 79955526048     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010372520     Document Type: Article

References (25)

1. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthritis Rheum. 2008 ; 58: 15-25
2. Chehata JC, Hassell AB, Clarke SA, et al. Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. Rheumatology (Oxford). 2001 ; 40: 447-452
3. Brennan FM, Maini RN, Feldmann M. TNF alpha - a pivotal role in rheumatoid arthritis?. Br J Rheumatol. 1992 ; 31: 293-298
4. Visvanathan S, Marini JC, Smolen JS, et al. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. J Rheumatol. 2007 ; 34: 1465-1474 (Pubitemid 47067980)
5. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2002 ; 2: 364-371 (Pubitemid 37328759)
6. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med. 2008 ; 148: 124-134 (Pubitemid 351651555)
7. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009 ; 68: 1136-1145
8. Malvern, Pa: Centocor Ortho Biotech ; 2009 :
9. Zhou H, Jang H, Fleischmann RM, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007 ; 47: 383-396 (Pubitemid 46294717)
10. Mascelli MA, Zhou H, Sweet R, et al. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J Clin Pharmacol. 2007 ; 47: 553-565 (Pubitemid 46632148)
11. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009 ; 68: 789-796
12. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000 ; 343: 1586-1593 (Pubitemid 32162981)
13. Krzyzanski W, Jusko WJ. Integrated functions for four basic models of indirect pharmacodynamic response. J Pharm Sci. 1998 ; 87: 67-72 (Pubitemid 28079263)
14. Efron B, Tibshirani RJ An Introduction to the Bootstrap. London: Chapman & Hall/CRC ; 1993 :
15. Xu Z, Vu T, Lee H, et al. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-α human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol. 2009 ; 49: 1056-1070
16. Schiff M, Weaver A, Keystone E. Comparison of ACR response, numeric ACR, and ACR AUC as measures of clinical improvement in RA clinical trials. Arthritis Rheum. 1999 ; 42: S81
17. Siegel JN, Zhen BG. Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in favor. Arthritis Rheum. 2005 ; 52: 1637-1641 (Pubitemid 40852869)
18. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008 ; 48: 303-332 (Pubitemid 351738156)
19. Hu C, Zhou H. An improved approach for confirmatory phase III population pharmacokinetic analysis. J Clin Pharmacol. 2008 ; 48: 812-822 (Pubitemid 351871963)
20. Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009 ; 49: 162-175
21. Zhang L, Beal SL, Sheiner LB. Simultaneous vs sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn. 2003 ; 30: 387-404 (Pubitemid 38221931)
22. Efron B. Estimating the error rate of a prediction rule: improvement on cross-validation. J Am Stat Assoc. 2009 ; 78: 316-331
23. Hu C, Sale M Pharmacometrics: The Science of Quantitative Pharmacology. Ette EI Williams P, ed. Hoboken, NJ: John Wiley ; 2007 :
24. Hu C, Moore KH, Kim YH, Sale ME. Statistical issues in a modeling approach to assessing bioequivalence or PK similarity with presence of sparsely sampled subjects. J Pharmacokinet Pharmacodyn. 2004 ; 31: 321-339 (Pubitemid 39287339)
25. Gibiansky L Population Approach Group in Europe: 2007. Copenhagen, Denmark: ; 2007 :